Pub. Date : 2013 Oct 1
PMID : 23856028
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | For MTC therapy, the Food and Drug Administration recently approved vandetanib and cabozantinib, multi-kinase inhibitors targeting RET and other tyrosine kinase receptors of vascular endothelial growth factor, epidermal growth factor, or hepatocyte growth factor. | vandetanib | vascular endothelial growth factor A | Homo sapiens |